Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma

Journal of Bone and Joint Surgery

Volumn 91, Issue 3, 2009, Pages 604-612

  Imran, Hamayun ^a   Enders, Felicity ^b   MarkKrailo, ^c   Sim, Franklin ^b   Okuno, Scott ^b   Hawkins, Douglas ^d   Neglia, Joseph ^e   Randall, R Lor ^f   Womer, Richard ^g   Mascarenhas, Leo ^h   Arndt, Carola A S ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b MAYO CLINIC   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62549083033     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/JBJS.H.00449     Document Type: Article

References (19)

1. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR, editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. NIH pub. no. 99-4649. Bethesda, MD: National Cancer Institute; 1999. p 99-110.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 2002;20:776-90.
3. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G; Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose metho- trexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-52.
4. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C; Italian Sarcoma Group/ Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, Adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/ Scandinavian Sarcoma Group pilot study. J Chemother. 2002;14:198-206.
5. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link
6. M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-11.
7. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M, Picci P. Adjuvant and neo- adjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836-45.
8. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC. Influence of metho- trexate dose intensity on outcome of patients with high grade osteogenic osteo- sarcoma. Analysis of the literature. Cancer. 1996;78:2127-35.
9. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83:1460-70.
10. Bacci G, Picci P, Avella M, Dallari D, Ferrari S, Prasad R, Di Scioscio M, Malaguti C, Caldora P. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and Adriamycin used preoperatively. J Chemother. 1990;2:127-35.
11. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
12. Arndt C, Miser J, Pritchard D, Sim F, Rock M, Shives T, Neglia J, Bostrom B, Nachman J, Gaynon P, Sato J, Ettinger L, Hutchinson R, Wold L. Treatment of high- grade osteosarcoma (OGS) with ifosfamide (IFOS), mesna (MES), Adriamycin (ADR), high-dose methotrexate (HDMTX), and cisplatin (CDDP) [abstract]. Med Pediatr Oncol. 1996;27:227a.
13. Miser J, Arndt C, Smithson W, Gilchrist G, Edmonson J, Sim F, Rock M, Pritchard D, Shives T, Wold L, Schaid D, Woods W, Neglia J, Thompson R, Nachman J, Gaynon P, Wiersma S, Hutchinson R, Sato J, Bostrom B, Thatcher G, Nickerson J, Ettinger L, Pendergrass T, Mason J, Swenson B, Conrad E. Treatment of high-grade osteosarcoma (OGS) with ifosfamide (IFOS), mesna (MES), Adriamycin (ADR), high- dose methotrexate (HDMTX), with or without cisplatin (CDDP); results of two pilot trials [abstract]. Proc Am Soc Clin Oncol. 1994;13:A1442.
14. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
15. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res. 2003;415:4-18.
16. Eselgrim M, Grunert H, Kuhne T, Zoubek A, Kevric M, Burger H, Jurgens H, Mayer-Steinacker R, Gosheger G, Bielack SS. Dose intensity of chemotherapy for
17. osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42-50.
18. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol. 2000;18:4028-37.
19. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH; MRC BO06 and EORTC 80931 collaborators; European Osteosar- coma Intergroup. Improvement in histologic response but not survival in osteo- sarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-28.